News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,063 Results
Type
Article (38988)
Company Profile (277)
Press Release (644798)
Section
Business (203839)
Career Advice (1987)
Deals (35358)
Drug Delivery (84)
Drug Development (80773)
Employer Resources (168)
FDA (16085)
Job Trends (14800)
News (344485)
Policy (32431)
Tag
Academia (2530)
Alliances (49042)
Alzheimer's disease (1218)
Approvals (16005)
Artificial intelligence (122)
Bankruptcy (352)
Best Places to Work (11489)
Biotechnology (196)
Breast cancer (111)
Cancer (968)
Cardiovascular disease (82)
Career advice (1657)
Cell therapy (209)
Clinical research (64000)
Collaboration (339)
Compensation (173)
COVID-19 (2523)
C-suite (85)
Data (940)
Diabetes (140)
Diagnostics (6113)
Earnings (84489)
Employer resources (146)
Events (109114)
Executive appointments (256)
FDA (16550)
Funding (301)
Gene therapy (153)
GLP-1 (566)
Government (4320)
Healthcare (18659)
Infectious disease (2602)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16275)
Job creations (3623)
Job search strategy (1415)
Layoffs (409)
Legal (7849)
Lung cancer (158)
Manufacturing (159)
Medical device (13152)
Medtech (13157)
Mergers & acquisitions (19120)
Metabolic disorders (375)
Neuroscience (1462)
NextGen Class of 2024 (6497)
Non-profit (4463)
Northern California (1304)
Obesity (223)
Opinion (176)
Patents (96)
People (56158)
Phase I (19867)
Phase II (28179)
Phase III (21032)
Pipeline (320)
Postmarket research (2553)
Preclinical (8452)
Radiopharmaceuticals (234)
Rare diseases (189)
Real estate (5888)
Regulatory (21460)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1163)
Startups (3560)
United States (12285)
Vaccines (541)
Weight loss (163)
Date
Today (232)
Last 7 days (1068)
Last 30 days (3276)
Last 365 days (35456)
2024 (31168)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31319)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (188)
Asia (37044)
Australia (6040)
California (2936)
Canada (1207)
China (224)
Colorado (127)
Connecticut (131)
Europe (79308)
Florida (415)
Georgia (104)
Illinois (320)
Indiana (187)
Kansas (96)
Maryland (543)
Massachusetts (2374)
Michigan (146)
Minnesota (257)
New Jersey (868)
New York (876)
North Carolina (674)
Northern California (1304)
Ohio (129)
Pennsylvania (780)
South America (1091)
Southern California (1163)
Texas (404)
Utah (84)
Washington State (335)
684,063 Results for "biocardia inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
BioCardia ® , Inc. today announces that the Unites States Patent Office has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a patent term that will expire in 2036.
June 7, 2024
·
4 min read
Biotech Bay
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.
May 1, 2024
·
5 min read
Biotech Bay
BioCardia Announces Reverse Stock Split - May 21, 2024
BioCardia, Inc. announced that, following approval by the Company’s stockholders and its Board of Directors, the Company intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares.
May 21, 2024
·
5 min read
Business
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2024 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2024 with the Securities and Exchange Commission.
May 14, 2024
·
12 min read
Biotech Bay
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
BioCardia, Inc. and StemCardia, Inc. announced a long-term partnership to advance StemCardia’s investigational pluripotent stem cell product candidate for the treatment of heart failure.
March 13, 2024
·
4 min read
Press Releases
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
November 6, 2024
·
1 min read
Biotech Bay
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
BioCardia®, Inc. announced it will report its financial results for the the three months ended March 31, 2024 and provide a corporate update by conference call on Tuesday, May 14, 2024 at 4:30 PM ET.
May 9, 2024
·
2 min read
Press Releases
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
September 18, 2024
·
3 min read
Press Releases
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
October 28, 2024
·
6 min read
Biotech Bay
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
BioCardia ®, Inc. today announced it will report its financial results for the year ended December 31, 2023 and provide a corporate update by conference call on Wednesday, March 27, 2024 at 4:30 PM ET.
March 20, 2024
·
1 min read
1 of 68,407
Next
